Abstract
Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 393-395 |
| Number of pages | 3 |
| Journal | Cancer clinical trials |
| Volume | 4 |
| Issue number | 4 |
| State | Published - Dec 1981 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine
